Considering the role of OLIG2 in restricting neural stem cell differentiation, and the role of OLIG2-expressing tumor stem cells in SHH-MB recurrence, we investigated whether pharmacologic disruption of OLIG2 would enhance MB therapy by targeting stem cells that may be resistant to radiation and cytotoxic chemotherapy. This evidence concerns the gene OLIG2 and neoplasm.